EUVIMEDEUVIMED entdecken
Crossref

1169-OR: Technology, Pharmacology, or Both? Real-World Effectiveness of CGM and GLP-1 Therapy in Primary Care

JOVAN MILOSAVLJEVIC, LORENA RASQUIN LEON, CLYDE SCHECHTER, SHIVANI AGARWAL

Diabetes · 06.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1169-or ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 06.06.2026. Verfasst von JOVAN MILOSAVLJEVIC und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: CGM and GLP-1 receptor agonists (RA) are two distinct and increasingly used treatment strategies in T2D, each associated with meaningful improvements in clinical outcomes. However, there is little real-world evidence comparing their effectiveness in primary care or evaluating whether combined use offers added benefit in HbA1c and body weight (BW).

Methods

We conducted a cohort study of adults with insulin-treated T2D (BMI ≥27 kg/m²) receiving primary care from 2020-2025 in a safety-net hospital system. Patients newly initiating CGM, GLP-1 RA, or both were followed while remaining on initial therapy. Inverse probability of treatment weighted mixed effects models were used to estimate longitudinal changes in HbA1c and BW.

Results

Among 6,169 adults (mean age 58±14 y, 45% Hispanic, 29% CGM, 63% GLP-1 RA, 8% combination), both HbA1c and BW demonstrated a clear stepwise improvement favoring combination therapy. At 1 yr, HbA1c declined by 0.85 %pt [0.94, 0.75] with CGM, 1.16 %pt [1.24, 1.08] with GLP-1 RA, and 1.70 %pt [1.81, 1.61] with combination therapy, while 1-yr percent BW loss was 0.74% [1.02, 0.46], 2.80% [3.07, 2.54], and 3.24% [3.48, 2.99], respectively (Figure).

Conclusion

Both CGM and GLP-1 RA were associated with meaningful improvements in HbA1c and weight, with the greatest benefit observed with combined use. These findings suggest complementary treatment effects and support a bundled, multimodal approach to T2D care in primary care settings. Disclosure J. Milosavljevic: None. L. Rasquin Leon: None. C. Schechter: None. S. Agarwal: None. Funding American Diabetes Association (7-25-JDFPC-0403)

Zitieren

APA

MILOSAVLJEVIC, J., LEON, L. R., SCHECHTER, C., & AGARWAL, S. (2026). 1169-OR: Technology, Pharmacology, or Both? Real-World Effectiveness of CGM and GLP-1 Therapy in Primary Care. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1169-or

Vancouver

MILOSAVLJEVIC J, LEON LR, SCHECHTER C, AGARWAL S. 1169-OR: Technology, Pharmacology, or Both? Real-World Effectiveness of CGM and GLP-1 Therapy in Primary Care. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1169-or

BibTeX
@article{MILOSAVLJEVIC2026,
  author = {MILOSAVLJEVIC, JOVAN and LEON, LORENA RASQUIN and SCHECHTER, CLYDE and AGARWAL, SHIVANI},
  title = {1169-OR: Technology, Pharmacology, or Both? Real-World Effectiveness of CGM and GLP-1 Therapy in Primary Care},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1169-or}
}
Kostenlos starten →